Media coverage about Proteostasis Therapeutics (NASDAQ:PTI) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.9738166757194 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Proteostasis Therapeutics’ FDA Breakthrough Therapy Designation Gives It An Edge – Seeking Alpha (seekingalpha.com)
- Proteostasis Therapeutics (PTI) Announces Withdrawal of Equity Offering Due to Market Conditions – StreetInsider.com (streetinsider.com)
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Proteostasis Therapeutics … – PR Newswire (press release) (prnewswire.com)
- Bragar Eagel & Squire, PC is Investigating Proteostasis Therapeutics, Inc. (PTI) on Behalf of Stockholders and … – Business Wire (press release) (businesswire.com)
- Scott+Scott Attorneys at Law LLP Announces Investigation into Proteostasis Therapeutics, Inc. (PTI) – PR Newswire (press release) (prnewswire.com)
Several equities analysts have commented on PTI shares. Robert W. Baird increased their target price on Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. ValuEngine downgraded Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Leerink Swann raised their price objective on Proteostasis Therapeutics from $6.00 to $8.00 in a research note on Tuesday, December 12th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a research note on Tuesday, December 19th. Finally, Zacks Investment Research cut Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $13.45.
TRADEMARK VIOLATION WARNING: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/2018/03/22/proteostasis-therapeutics-pti-receives-daily-coverage-optimism-score-of-0-03/1926336.html.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.